Related Experiment Videos
[Tumor markers in urological malignancies]
1Department of Urology, Gifu University School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 1, 1996
Summary
Specific tumor markers for kidney, urothelium, and penile cancers remain elusive. However, alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG) are vital for testicular tumors, while prostate-specific antigen (PSA) is crucial for prostate cancer.
Area of Science:
- Uro-oncology
- Tumor marker research
- Diagnostic oncology
Context:
- Review of current tumor marker applications in urological cancers.
- Identifies gaps in diagnostic specificity for kidney, urothelium, and penile tumors.
- Highlights established markers in testicular and prostate malignancies.
Purpose:
- To assess the present status of tumor markers in urological malignancies.
- To evaluate their utility in diagnosis and patient follow-up.
- To identify areas for future research and standardization.
Summary:
- Alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (beta-HCG) are key markers for testicular tumors, aiding in residual disease and recurrence detection via biological half-life monitoring.
- Prostate-specific antigen (PSA) is the most effective tumor marker for prostate cancer, a solid tumor.
- Further research is needed for kidney, urothelium, and penile cancers, alongside global standardization and subtype evaluation of PSA assays.
Impact:
- Informs clinical practice regarding the use of existing tumor markers.
- Guides future research directions for developing novel markers in urological cancers.
- Emphasizes the need for standardization in prostate-specific antigen (PSA) testing for improved accuracy and comparability.